Life Sciences & Biotechnology

CSIR-IMTECH has developed two mass-production ready plate based kits to estimate plasma gelsolin levels in humans. Plasma gelsolin is fast emerging as a health condition biomarker and its repletion in compromised cases is under Phase 1 and 2 trials. While, most other labs including commercial set-ups are focusing on improving bulk production of this protein, IMTECH has developed bonsai versions of this protein by structure-based insights. IMTECH successfully demonstrated the anti-sepsis properties of miniaturized versions in LPS-induced sepsis model of mice (Peddada et al., 2013). This project is part of the objective proposed in 12 FYP BioDiscovery where IMTECH proposed to design mini-proteins or peptides capable of rescuing sepsis condition. The kits which have been developed in IMTECH will help in determining a quantitative measure of the sepsis. Alongside, we are testing the kits viability in predicting cases of preterm birth. Both kits come with a cell phone based application for measuring the gelsolin value and providing a prognosis on the patient status.